Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing

Area of Science:

• Immunology
• Biotechnology
• Cell Therapy Manufacturing

Background:

• Allogeneic T cells are crucial for cancer immunotherapy and other clinical applications.
• Increasing patient numbers and required cell doses necessitate scalable T cell manufacturing.
• Current methods face challenges in scaling up while maintaining cell quality and reducing contamination risks.

Purpose of the Study:

• To present a closed and scalable manufacturing platform for allogeneic T cell production.
• To demonstrate the integration of upstream and downstream processes for enhanced efficiency.
• To ensure high cell quality and robust process control for clinical applications.

Main Methods:

• Utilized a stirred-tank bioreactor for in-vessel T cell activation and expansion.
• Integrated T cell selection within the bioreactor to maintain optimal culture conditions.
• Incorporated automation for enhanced process control, reduced manual labor, and minimized contamination risk.
• Demonstrated a closed, automated downstream process for cell concentration.

Main Results:

• The platform successfully scaled T cell manufacturing while preserving cell quality.
• In-vessel processing for activation, expansion, and selection improved process control.
• Automation significantly reduced manual labor and the risk of contamination.
• Integration of downstream processing was viable, demonstrating a complete manufacturing solution.

Conclusions:

• The presented platform offers a scalable solution for allogeneic T cell manufacturing.
• Automation and in-vessel processing are key to enhancing cell therapy production.
• This platform meets the growing clinical demand for high-quality T cells.
• The system supports robust process control and reduces manufacturing risks.